Potential contribution of pineal atrophy and pineal cysts toward vulnerability and clinical characteristics of psychosis.
Clinical high risk
Magnetic resonance imaging
Melatonin
Pineal gland
Psychosis
Schizophrenia
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
05
2021
revised:
31
07
2021
accepted:
20
08
2021
pubmed:
31
8
2021
medline:
20
1
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Magnetic resonance imaging (MRI) studies reported pineal gland atrophy in schizophrenia patients and individuals at a clinical high risk of developing psychosis, implicating abnormalities in melatonin secretion in the pathophysiology of psychosis. However, it currently remains unclear whether the morphology of the pineal gland contributes to symptomatology and sociocognitive functions. This MRI study examined pineal gland volumes and the prevalence of pineal cysts as well as their relationship with clinical characteristics in 57 at risk mental state (ARMS) subjects, 63 patients with schizophrenia, and 61 healthy controls. The Social and Occupational Functioning Assessment Scale (SOFAS), the Schizophrenia Cognition Rating Scale (SCoRS), and the Brief Assessment of Cognition in Schizophrenia (BACS) were used to assess sociocognitive functions, while the Positive and Negative Syndrome Scale was employed to evaluate clinical symptoms in ARMS subjects and schizophrenia patients. Pineal gland volumes were significantly smaller in the ARMS and schizophrenia groups than in the controls, while no significant differences were observed in the prevalence of pineal cysts. Although BACS, SCoRS, and SOFAS scores were not associated with pineal morphology, patients with pineal cysts in the schizophrenia group exhibited severe positive psychotic symptoms with rather mild negative symptoms. The present results indicate the potential of pineal atrophy as a vulnerability marker in various stages of psychosis and suggest that pineal cysts influence the clinical subtype of schizophrenia.
Sections du résumé
BACKGROUND
Magnetic resonance imaging (MRI) studies reported pineal gland atrophy in schizophrenia patients and individuals at a clinical high risk of developing psychosis, implicating abnormalities in melatonin secretion in the pathophysiology of psychosis. However, it currently remains unclear whether the morphology of the pineal gland contributes to symptomatology and sociocognitive functions.
METHODS
This MRI study examined pineal gland volumes and the prevalence of pineal cysts as well as their relationship with clinical characteristics in 57 at risk mental state (ARMS) subjects, 63 patients with schizophrenia, and 61 healthy controls. The Social and Occupational Functioning Assessment Scale (SOFAS), the Schizophrenia Cognition Rating Scale (SCoRS), and the Brief Assessment of Cognition in Schizophrenia (BACS) were used to assess sociocognitive functions, while the Positive and Negative Syndrome Scale was employed to evaluate clinical symptoms in ARMS subjects and schizophrenia patients.
RESULTS
Pineal gland volumes were significantly smaller in the ARMS and schizophrenia groups than in the controls, while no significant differences were observed in the prevalence of pineal cysts. Although BACS, SCoRS, and SOFAS scores were not associated with pineal morphology, patients with pineal cysts in the schizophrenia group exhibited severe positive psychotic symptoms with rather mild negative symptoms.
CONCLUSION
The present results indicate the potential of pineal atrophy as a vulnerability marker in various stages of psychosis and suggest that pineal cysts influence the clinical subtype of schizophrenia.
Identifiants
pubmed: 34461434
pii: S2213-1582(21)00249-7
doi: 10.1016/j.nicl.2021.102805
pmc: PMC8405969
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102805Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):877-86
pubmed: 21300129
Psychiatry Res Neuroimaging. 2019 Jan 30;283:92-95
pubmed: 30576941
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychiatry Res Neuroimaging. 2019 Jul 30;289:13-17
pubmed: 31121531
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):689-698
pubmed: 29071372
Arch Gen Psychiatry. 2012 Jun;69(6):562-71
pubmed: 22664547
Front Behav Neurosci. 2021 Apr 20;15:647069
pubmed: 33958991
Curr Clin Pharmacol. 2014;9(4):326-34
pubmed: 24050742
Mol Cell Endocrinol. 2012 Feb 5;349(1):13-9
pubmed: 21782887
Int J Neurosci. 1990 Aug;53(2-4):217-22
pubmed: 1979970
Front Cell Neurosci. 2013 May 15;7:60
pubmed: 23720610
J Pineal Res. 2005 Apr;38(3):145-52
pubmed: 15725334
Psychiatry Res Neuroimaging. 2017 Aug 30;266:10-18
pubmed: 28549318
Schizophr Res. 2011 Jan;125(1):1-12
pubmed: 20965698
Schizophr Res. 2015 Jan;161(1):19-28
pubmed: 24893909
Pharmacol Biochem Behav. 2017 Nov;162:3-21
pubmed: 28647565
Metab Brain Dis. 2019 Jun;34(3):865-874
pubmed: 30758707
AJNR Am J Neuroradiol. 2007 Oct;28(9):1706-9
pubmed: 17885233
Schizophr Res. 2015 May;164(1-3):28-34
pubmed: 25749019
Front Neuroendocrinol. 2001 Jan;22(1):18-32
pubmed: 11141317
Br J Psychiatry. 2011 Apr;198(4):269-76
pubmed: 21263013
Psychiatry Res Neuroimaging. 2017 Dec 30;270:8-21
pubmed: 28988022
Sci Rep. 2020 Jul 2;10(1):10957
pubmed: 32616764
Brain Imaging Behav. 2017 Dec;11(6):1741-1750
pubmed: 27812851
J Magn Reson Imaging. 2014 Oct;40(4):966-71
pubmed: 24214660
Schizophr Res. 1995 Feb;14(3):253-5
pubmed: 7766537
Int J Neurosci. 1992 Nov-Dec;67(1-4):9-17
pubmed: 1305641
Neurosci Lett. 2002 Aug 30;329(2):246-8
pubmed: 12165423
Int J Neurosci. 1991 Apr;57(3-4):179-91
pubmed: 1938161
Psychoneuroendocrinology. 2019 Jun;104:100-114
pubmed: 30831343
Psychiatry Res. 2017 Nov;257:431-437
pubmed: 28837932
Front Psychiatry. 2020 May 20;11:450
pubmed: 32528324
Neuropsychobiology. 1997;36(4):159-63
pubmed: 9396013
AJR Am J Roentgenol. 2001 Mar;176(3):737-43
pubmed: 11222216
J Pineal Res. 2017 Oct;63(3):
pubmed: 28500770
Schizophr Bull. 2016 Jan;42(1):229-38
pubmed: 26187283
J Neuroendocrinol. 2003 Apr;15(4):432-7
pubmed: 12622846
Acta Psychiatr Scand. 1991 Sep;84(3):221-4
pubmed: 1950621
J Neurosurg. 2011 Dec;115(6):1106-14
pubmed: 21780858
Am J Psychiatry. 2006 Mar;163(3):426-32
pubmed: 16513863
J Magn Reson Imaging. 2009 Sep;30(3):499-505
pubmed: 19630077
Psychiatr Danub. 2015 Jun;27(2):153-8
pubmed: 26057310
Schizophr Res. 2019 Apr;206:163-170
pubmed: 30527931
Dev Med Child Neurol. 2014 Aug;56(8):717-23
pubmed: 24575840
Am J Psychiatry. 1992 Sep;149(9):1148-56
pubmed: 1386964
J Med Life. 2014 Oct-Dec;7(4):488-92
pubmed: 25713608
Metab Brain Dis. 2012 Jun;27(2):113-9
pubmed: 22527998
Int J Dev Neurosci. 2009 Nov;27(7):655-60
pubmed: 19665543